Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Coherus Bio (CHRS)

20.43   0.88 (4.5%) 01-27 02:17
Open: 19.76 Pre. Close: 19.55
High: 20.64 Low: 19.29
Volume: 1,639,869 Market Cap: 1,472M
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.665 - 20.744 20.744 - 20.824
Low: 19.089 - 19.181 19.181 - 19.273
Close: 20.276 - 20.422 20.422 - 20.568

Technical analysis

as of: 2021-01-26 4:42:14 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 24.11     One year: 28.16
Support: Support1: 18.14    Support2: 16.60
Resistance: Resistance1: 20.64    Resistance2: 24.11
Pivot: 18.05
Moving Average: MA(5): 18.92     MA(20): 17.83
MA(100): 18.00     MA(250): 17.91
MACD: MACD(12,26): 0.40     Signal(9): 0.11
Stochastic oscillator: %K(14,3): 87.02     %D(3): 83.51
RSI: RSI(14): 70.83
52-week: High: 23.03  Low: 10.86  Change(%): 8.8
Average Vol(K): 3-Month: 93364  10-Days: 126148

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
CHRS has closed above the upper band by 17.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 77.9% wider than normal. The large width of the bands suggest high volatility as compared to CHRS's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue.

Headline News

Mon, 21 Dec 2020
Coherus BioSciences Announces New Employment Inducement Grants - GlobeNewswire

Fri, 06 Nov 2020
Coherus BioSciences Inc (CHRS) Q3 2020 Earnings Call Transcript - Motley Fool

Thu, 05 Nov 2020
Coherus BioSciences Reports Third Quarter 2020 Financial Results - GlobeNewswire

Thu, 22 Oct 2020
Coherus BioSciences to Report Third Quarter Financial Results on November 5th - GlobeNewswire

Thu, 06 Aug 2020
Coherus BioSciences Reports Second Quarter 2020 Financial Results - GlobeNewswire

Mon, 03 Aug 2020
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 72
Shares Float (M) 60
% Held by Insiders 1.62
% Held by Institutions 125.64
Shares Short (K) 14,600
Shares Short P. Month (K) 15,760

Stock Financials

EPS 2.050
EPS Est This Year -5.130
EPS Est Next Year -2.620
Book Value (p.s.) 3.550
Profit Margin 33.06
Operating Margin 37.82
Return on Assets (ttm) 20.5
Return on Equity (ttm) 103.8
Qtrly Rev. Growth 1.7
Gross Profit (p.s.) 3.399
Sales Per Share 6.791
EBITDA (p.s.) 2.611
Qtrly Earnings Growth -40.60
Operating Cash Flow (M) 139
Levered Free Cash Flow (M) 52

Stock Valuations

PE Ratio 9.97
PEG Ratio
Price to Book value 5.75
Price to Sales 3.01
Price to Cash Flow 10.61

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.